Takeda Pharmaceutical Statistics
Share Statistics
Takeda Pharmaceutical has 3.17B
shares outstanding. The number of shares has increased by 1.03%
in one year.
| Shares Outstanding | 3.17B |
| Shares Change (YoY) | 1.03% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 4.55% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 365 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 45.02 and the forward
PE ratio is 0.34.
Takeda Pharmaceutical's PEG ratio is
-0.82.
| PE Ratio | 45.02 |
| Forward PE | 0.34 |
| PS Ratio | 1.52 |
| Forward PS | 0 |
| PB Ratio | 0.89 |
| P/FCF Ratio | 27.53 |
| PEG Ratio | -0.82 |
Financial Ratio HistoryEnterprise Valuation
Takeda Pharmaceutical has an Enterprise Value (EV) of 7,629B.
| EV / Sales | 1.79 |
| EV / EBITDA | 8.72 |
| EV / EBIT | 10.65 |
| EV / FCF | 32.38 |
Financial Position
The company has a current ratio of 1.11,
with a Debt / Equity ratio of 0.67.
| Current Ratio | 1.11 |
| Quick Ratio | 0.58 |
| Debt / Equity | 0.67 |
| Debt / EBITDA | 5.54 |
| Debt / FCF | 20.56 |
| Interest Coverage | 1.39 |
Financial Efficiency
Return on Equity is 1.98% and Return on Invested Capital is 4.44%.
| Return on Equity | 1.98% |
| Return on Assets | 0.95% |
| Return on Invested Capital | 4.44% |
| Revenue Per Employee | $86,519,388.81 |
| Profits Per Employee | $2,923,378.18 |
| Employee Count | 49,281 |
| Asset Turnover | 0.28 |
| Inventory Turnover | 1.18 |
Taxes
| Income Tax | -91.41B |
| Effective Tax Rate | -173.15% |
Stock Price Statistics
The stock price has increased by 6.88% in the
last 52 weeks. The beta is 0.26, so Takeda Pharmaceutical's
price volatility has been higher than the market average.
| Beta | 0.26 |
| 52-Week Price Change | 6.88% |
| 50-Day Moving Average | 14.89 |
| 200-Day Moving Average | 14.14 |
| Relative Strength Index (RSI) | 38.42 |
| Average Volume (20 Days) | 1,886,522 |
Income Statement
In the last 12 months, Takeda Pharmaceutical had revenue of 4,263.8B
and earned 144.07B
in profits. Earnings per share was 46.05.
| Revenue | 4,263.8B |
| Gross Profit | 2,832.3B |
| Operating Income | 214.07B |
| Net Income | 144.07B |
| EBITDA | 874.6B |
| EBIT | 172.33B |
| Earnings Per Share (EPS) | 46.05 |
Full Income StatementBalance Sheet
The company has 457.8B in cash and 4,843.8B in
debt, giving a net cash position of -4,386B.
| Cash & Cash Equivalents | 457.8B |
| Total Debt | 4,843.8B |
| Net Cash | -4,386B |
| Retained Earnings | 1,391.2B |
| Total Assets | 14,573B |
| Working Capital | 666.78B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 716.34B
and capital expenditures -480.73B, giving a free cash flow of 235.61B.
| Operating Cash Flow | 716.34B |
| Capital Expenditures | -480.73B |
| Free Cash Flow | 235.61B |
| FCF Per Share | 150.61 |
Full Cash Flow StatementMargins
Gross margin is 66.43%, with operating and profit margins of 5.02% and 3.38%.
| Gross Margin | 66.43% |
| Operating Margin | 5.02% |
| Pretax Margin | 1.24% |
| Profit Margin | 3.38% |
| EBITDA Margin | 20.51% |
| EBIT Margin | 5.02% |
| FCF Margin | 5.53% |
